Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Tables)

v3.10.0.1
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Schedule of milestone payments

  Milestones   Payments  
         
  (1) filing of a New Drug Application (“NDA”) or regulatory approval for each licensed product   $ 750,000  
  (2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product     1,750,000